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We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene
expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under
the transcriptional control of the tetO/promoter. Human melanoma cells were transduced by two modiﬁed retroviral tet vectors
containing the transactivator regulatory unit and the IL-2 gene driven by the tetO/promoter, respectively. In the absence of tet, IL-2
expression in the target cells was stable over several months. IL-2 production was in the range of 40 U/10
6 cells/24 hours. A ﬁne
tuning of IL-2 expression could be achieved by culturing the transduced cells with increasing doses of tet, whereby a concentration
of 500 ng/mL tet in the culture medium abrogated IL-2 expression. Most importantly for clinical application, IL-2 expression by the
transduced melanoma cells could also be regulated in vivo. When nu/nu mice were inoculated with the transduced tumor cells,
they failed to develop tumors. Instead, the inhibition of IL-2 expression in the transduced tumor cells by oral administration of tet
led to subcutaneous tumor growth; this growth rate was comparable with the growth rate of subcutaneously inoculated
untransduced parental cells. The ﬁnding demonstrates the applicability of the tet-regulated system in cancer gene therapy.
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A
high level of expression and the controllable deliv-
ery of gene products constitute two important
parameters to accomplish effective gene therapy. The
choice of an adequate expression vector system could be
an important tool to assess the optimal expression of the
target gene. A system that answers these questions has
been described recently.
1 Target genes are placed under
the control of regulatory sequences (tetO) from the
tetracycline (tet)-resistance operon of transposon 10.
The tet-regulated system is composed of two elements,
each of which is carried on a separate plasmid vector.
One component, the regulator unit, encodes the trans-
activator (tTA). tTA is a fusion protein composed of the
tet repressor of Escherichia coli and the transcriptional
activation domain of the VP16 protein of the herpes
simplex virus. The second component, the response unit,
is composed of the E. coli-derived tet resistance operon
regulatory element (tetO) embedded within a minimal
cytomegalovirus (CMV) promoter. Expression of a tar-
get gene inserted downstream of the tetO/minimal CMV
promoter is dependent upon the tTA, which binds tetO
sequences. In the presence of the antibiotic, the binding
of the tTA to the tetO promoter is impaired, resulting in
shutoff of target gene expression in cultured cells
1–6 and
transgenic mice.
7–10 In the absence of the antibiotic,
expression of the target gene is induced.
The tet-regulated system allows not only a qualitative
off-on transition but also a ﬁne tuning of gene expression
with different tet concentrations.
1,11,12 Regulation is
restricted to the target gene, and host genes are not
affected. The required tet concentrations seem nontoxic.
1
We have used a retroviral modiﬁcation of the tet-
regulated system to evaluate the feasibility of controlled
gene expression in tumor therapy. As a model system,
we manipulated the expression of the human interleu-
kin-2 (IL-2) gene in the human melanoma cell line
MeWo. In the animal model, we could demonstrate the
efﬁcacy of IL-2 expression in mounting an antitumor
response of tumor cells expressing IL-2, which has been
described repeatedly.
13–17 In the absence of tet, the
expression of IL-2 by the tumor cells prevented subcu-
taneous (s.c.) growth of the melanoma cells in nu/nu
mice. Instead, tumor growth was unimpaired when IL-2
expression was abolished by a supply of the antibiotic in
the drinking water. This ﬁnding demonstrates for the
ﬁrst time the applicability of the retroviral tet-regulated
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Cancer Gene Therapy, Vol 6, No 2, 1999: pp 139–146 139system in cancer gene therapy. The model creates pros-
pects for in vivo manipulation of immunologically and
therapeutically relevant genes.
MATERIALS AND METHODS
Cell culture
The retroviral packaging cell lines Bosc23 and PA317, NIH3T3
(mouse embryo ﬁbroblasts), HeLa (human cervix carcinoma
cell line), and CTLL-2 (cytotoxic T-lymphocyte line 2) were
purchased from the American Type Culture Collection (Man-
assas, Va). The human melanoma cell line MeWo has been
described previously by Bean et al.
18 All cell lines were
maintained at 37°C in 5% CO2 and Dulbecco’s modiﬁed
Eagle’s medium (Life Technologies, Eggenstein, Germany)
supplemented with 10% fetal bovine sera (Sigma, Deisen-
hofen, Germany), 1% glutamine, and 1% penicillin-streptomy-
cin (Life Technologies). CTLL-2 cells were cultured in RPMI
1640 medium (Life Technologies) containing 10% fetal bovine
sera and 20 international units/mL human recombinant IL-2
(rIL-2) (Chiron, Emeryville, Calif).
Retroviral vector constructs, viral production,
and transduction
The retroviral vector constructs are schematically illustrated in
Figure 1. SF6tTA and ECT2pbiIL-2 are based on the retroviral
vector SFG (kindly provided by R. Mulligan, Harvard Medical
School, Boston, Mass). The plasmid SF6tTA was constructed
by inserting the transactivator regulator element tTA from
pUHD15-1
1 and the neomycin resistance marker gene.
ECT2pbiIL-2 contains the human IL-2 gene, which is con-
trolled by the tetO/promoter. In this construct tetO is ﬂanked
by two divergently orientated CMV minimal promoters (the
bidirectional promoter, pbi
11). The human IL-2 gene and its
tetO/promoter are located in antisense orientation relative to
the 59 long terminal repeat (LTR), so that the human IL-2
gene is driven only by the tetO/promoter.
For packaging of the constructed vectors, 10 mg of each
plasmid DNA was transfected into the helper-free ecotropic
packaging cell line Bosc23 by calcium phosphate precipitation
as described previously.
19 The virus supernatant of Bosc23 was
harvested after 48 hours, passed through a 0.45-mm ﬁlter,
adjusted to 8 mg/mL polybrene, and used to transduce the
amphotropic packaging cell line PA317.
The PA317 cells transduced with SF6tTA were selected for
G418 resistance at a concentration of 400 mg/mL. Individual
colonies were analyzed for tTA expression using reverse
transcriptase-polymerase chain reaction (RT-PCR). Viral ti-
ters were tested by their capacity to confer G418 resistance to
NIH3T3 cells. The viral supernatant of the producer colony
that showed the highest titer (2 3 10
6 colony-forming units/
mL, data not shown) and tTA expression was used to generate
MeWo/tTA by the infection of parental MeWo cells. The
producer cell line PA317 was transduced with ECT2pbiIL-2,
and the virus-containing supernatant was used to infect a
clonal population of MeWo/tTA. Because a second selectable
marker gene was absent on the ECTpbiIL-2 plasmid, clonal
isolates of double transductants were generated by single-cell
plating on a 96-well plate. The resulting double transductant
MeWo-tTA/IL-2 was cultured in the absence and presence of
tet (500 ng/mL) in the culture medium.
Transfection and luciferase assay
NIH3T3 and HeLa cells (5 3 10
5) were ﬁrst transfected with 1
mg of the luciferase reporter plasmid pUHD131-1 by calcium
phosphate precipitation.
20 At 1 day after transfection, the
medium was changed. On the following day, cells were infected
with SF6tTA virus supernatant from the Bosc23 packaging cell
line (NIH3T3 target cells) or supernatant from the PA317
supernatant (HeLa target cells). At 2 days after infection, cells
Figure 1. Schematic representation of tet-regulatable retroviral vectors. SF6tTA contains the transactivator regulator unit tTA, which is under
the transcriptional control of the 59 retroviral LTR. The neomycin resistance gene (Neo) is under the transcriptional control of the internal
thymidine kinase promoter. ECT2pbiIL-2 contains the human IL-2 gene, which is controlled by the tetO/promoter. The tetO sequences are
ﬂanked by two divergently orientated minimal CMV promoters (bidirectional promoter, pbi). tTA, transactivator; TK, herpes simplex virus type
1 thymidine kinase promoter.
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phosphate-buffered saline and subsequently lysed in luciferase
extraction buffer (0.1 M potassium phosphate, 2 mM ethyl-
enediaminetetraacetic acid, 0.7 mM Triton X-100, and 1 mM
dithiothreitol) at 4°C. Cell lysates were collected from the plate
using a cell scraper and centrifuged. Aliquots (30 mL) of the
supernatant were mixed with 370 mL of luciferase reaction
buffer containing 25 mM glycylglycine, 1 mM adenosine
triphosphate, and 10 mM MgSO4 and assayed for luciferase
activity in a Lumat (Berthold, Wildbad, Germany). D-luciferin
was used at 0.5 mM. Luciferase activity was adjusted to the
protein content of the lysates using the Bradford assay (Bio-
Rad, Munich, Germany).
Determination of IL-2 production by enzyme-linked
immunosorbent assay (ELISA)
Supernatants were collected from MeWo-tTA/IL-2 cells
seeded at a density of 2 3 10
5. Culture supernatant was
assayed in triplicate for IL-2 production by ELISA. Brieﬂy,
96-well plates coated with an anti-human IL-2 monoclonal
antibody were incubated for 1 hour at 37°C with the test
samples. After three washes, the plates were incubated for 1
hour with horseradish peroxidase-conjugated goat anti-human
IL-2 according to the manufacturer’s protocol. The enzymatic
reaction was developed with a chromagen substrate, and
optical density was measured on an ELISA plate reader.
Determination of IL-2 production by the
CTLL-2 bioassay
The biological activity of IL-2 released by the transduced cells
was tested with an IL-2-dependent CTLL proliferation assay.
Brieﬂy, dilutions of MeWo-tTA/IL-2 culture supernatant
(treated with tet or left untreated) were transferred to a
96-well culture plate containing 3 3 10
4 CTLL-2 cells per well.
CTLL-2 cells cultured in RPMI 1640 medium or in a known
amount of IL-2 were used as negative and positive controls,
respectively. After 6 hours, 0.5 mCi of [
3H]thymidine was
added to each well, and the culture was incubated for an
additional 24 hours. Cells were harvested with a cell harvester
(Pharmacia, Uppsala, Sweden), and [
3H]thymidine incorpora-
tion was counted in a liquid scintillation counter (LKB, Turku,
Finland). A standard IL-2 curve containing known concentra-
tions permitted the quantitation of IL-2 levels.
IL-2 and tTA expression by RT-PCR
Producer cell lines and the double transductant MeWo-tTA/
IL-2 were tested for tTA and IL-2 gene expression. Total RNA
was extracted from 2 3 10
5 cells according to Chomczynski and
Sacchi.
21 A total of 2 mg of RNA was reverse transcribed to
cDNA using the standard protocol.
20 cDNA was subjected to
PCR ampliﬁcation. Reactions were performed in 50-mL reac-
tion mixtures that contained 50 mM KCl, 20 mM tris(hy-
droxymethyl)aminomethane-HCl, 1.5 mM MgCl2,1 5m Md e -
oxynucleoside triphosphate, 25 pmol of each primer, the
template DNA, and2Uo fTaq polymerase. The thermal cycler
proﬁle was as follows: 30 cycles of 60 seconds for denaturing at
94°C and 30 seconds for annealing/elongation at 50°C for the
IL-2 primers (R&D Systems, Minneapolis, Minn). For tTA
PCR, annealing was performed at 58°C for 45 seconds, and
elongation was accomplished at 64°C for 1 minute in the
40-cycle proﬁle. The ampliﬁed products were electrophoresed
in a 1.5% agarose gel.
Provirus integration by genomic PCR
Genomic DNA was isolated by cell lysis in 1% sodium dodecyl
sulfate, 200 mL proteinase K, 100 mM NaCl, 10 mM tris(hy-
droxymethyl)aminomethane, and 25 mM ethylenediaminetet-
raacetic acid at 55°C for 16 hours after DNA isolation;
isolation was accomplished by phenol-chloroform extraction
and ethanol precipitation.
20 A total of 1 mg of DNA was
ampliﬁed by PCR using tTA and the IL-2 gene-speciﬁc primers
according to the same protocol as described above.
Tumorigenicity in nu/nu mice
Parental MeWo cells and MeWo-tTA/IL-2 cells (previously
cultured in the presence and absence of tet) (5 3 10
6) were
procured from tissue culture ﬂasks, washed, and injected s.c.
into the ﬂanks of congenitally athymic nude mice. The group of
mice injected with tet-pretreated MeWo-tTA/IL-2 received
200 mg/mL tet dissolved in 5% sucrose supplied in the drinking
water, which was exchanged every 3 days. Bidirectional tumor
diameters were measured using a caliper at regular intervals
for 60 days.
Cytotoxicity assay
The natural killer (NK) activity of spleen cells from nu/nu mice
was assayed on MeWo target cells in a 4-hour
51Cr release
assay. For preactivation, spleen cells (3 3 10
6) were cultured
for 6 days in the presence and the absence of tet together with
3 3 10
5 irradiated (100 Gy) parental MeWo cells, IL-2-
transduced MeWo cells, and parental MeWo cells, for which
the culture medium contained 20 U of rIL-2.
Target cells were prepared by culturing cells for 2 hours in
the presence of 100 mCi of
51Cr. A total of 10
4 labeled target
cells per well were mixed with titrated amounts of effector cells
to yield effector to target ratios of 50–6:1 and were incubated
for 4 hours. Plates were centrifuged, and released radioactivity
was measured in 100-mL aliquots of the supernatants. Maxi-
mum release was determined by incubating the target cells with
2% sodium dodecyl sulfate; spontaneous release was measured
by incubating the target cells with the culture medium.
RESULTS
Tet-dependent regulation of luciferase activity with the
retroviral tTA transactivator construct SF6tTA
To test the activity of the retroviral transactivator con-
struct SF6tTA in the tet-dependent regulation system,
we used NIH3T3 and HeLa cells as target cells. At 2
days before infection, target cells were transiently trans-
fected with the luciferase reporter plasmid pUHD131-1
by calcium precipitation. NIH3T3 and HeLa cells were
then infected with the SF6tTA virus supernatant from
the Bosc23 and PA317 packaging cells, respectively, in
the presence (500 ng/mL) and absence of tet. The
luciferase activity of the pooled cells was determined 2
days thereafter. In the absence of tet, we observed an
elevation of luciferase activity of up to ;500-fold in both
cell lines (Table 1). This observation indicated that the
tTA gene driven by the internal 59 LTR promoter was
active. Furthermore, the tet-inducible system, including
the retroviral SF6tTA regulator unit in cooperation with
a tet promoter response unit, seemed tightly regulated.
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expressing IL-2 and tTA simultaneously
The retroviral vector constructs that were used to intro-
duce and express the tTA and the human IL-2 gene
simultaneously in the MeWo cell line are shown above
(Fig 1). As described in Materials and Methods, we ﬁrst
generated packaging cell lines that produce tTA and
IL-2 virus, respectively. The supernatants of the pro-
ducer cell lines were tested for viral titer and gene
expression either by RT-PCR analysis (tTA) or by
ELISA and the CTLL-2 bioassay (IL-2). The colonies
showing the highest viral titer and gene expression were
used to infect the target MeWo cell line. MeWo cells
were infected ﬁrst with the tTA containing virus super-
natant. Neomycin-resistant colonies were selected and
cloned. Thereafter, tTA
1 clones were infected with
IL-2-containing supernatant.
Clonal isolates of the double transductant MeWo-
tTA/IL-2 clones were analyzed for proviral DNA ampli-
ﬁcation and gene expression. Ampliﬁcation of the re-
spective proviral IL-2 and tTA genes is shown for one
clone by PCR of genomic DNA samples and by RT-PCR
for proviral mRNA (Fig 2). Untransduced MeWo cells
did not express the tTA gene or the IL-2 gene (data not
shown).
Tet-regulated expression of IL-2 and dose-dependent
expression of IL-2 at different tet concentrations
Several MeWo-tTA/IL-2 clones were cultured in the
absence of tet, and IL-2 production was determined by
ELISA and by CTLL-2 assay. The amount of IL-2
produced by the different MeWo-tTA/IL-2 clones varied
from 5 to 40 U/10
6 cells/24 hours (data not shown). The
clone that expressed the highest amount of IL-2 (40 U)
was selected for subsequent studies. Transfected MeWo-
tTA/IL-2 cells were then cultured in the presence of
increasing doses of tet, and the expression of IL-2 was
analyzed by RT-PCR and ELISA. Figure 3, A and B,
shows a gradual reduction of IL-2 expression with an
increasing dose of tet. The data indicated that IL-2
expression in the transduced tumor cells could be re-
duced gradually by increasing concentrations of tet; a
complete inhibition of IL-2 expression could be achieved
by 100 ng/mL tet.
Exposure to tet interferes with activation of NK cells
by IL-2-transduced tumor cells
As shown in Table 2 NK/lymphokine activated killer
(LAK) activity was signiﬁcantly increased after the co-
culture of spleen cells with the transduced MeWo-tTA/
IL-2. By adding tet to the culture medium, spleen cells
did not become activated and displayed cytotoxicity
values comparable with those obtained after coculture
Table 1. Tet-Dependent Regulation of Luciferase Activity with
the Retroviral Transactivator Construct SF6tTA
Luciferase activity
(rlu†/mg of total protein)
With tet Without tet Activation factor
NIH3T3* 540496 611 884
HeLa 436689 655 667
* NIH3T3 and HeLa cells were transiently transfected with the
luciferase reporter plasmid pUHD131-1 and infected with the
SF6tTA virus supernatant from the ecotropic Bosc23 (for NIH3T3
cells) or the amphotropic PA317 (for HeLa cells) packaging cells.
Luciferase activity in the absence and the presence (500 ng/mL)
of tet reﬂects the inducible regulation. Values are the arithmetic
means of three independent luciferase determinations (in
triplicate).
† rlu, relative light units.
Figure 2. Provirus integration and expression shown by DNA (A)
and RT-PCR (B). DNA and RNA were isolated from the transduced
MeWo-tTA/IL-2 cells and the parental MeWo cells and were ampli-
ﬁed using tTA and IL-2-speciﬁc primers. Ampliﬁed products were
separated on a 1.5% agarose gel stained with ethidium bromide.
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not inﬂuence the activation of NK cells, because NK
cells became activated to the same degree in cultures
containing exogenous IL-2 or exogenous IL-2 plus tet.
This ﬁnding demonstrated that the secreted IL-2 is
biologically active and that the supply of tet has no toxic
effects on NK/LAK cells.
Tumorigenicity in nude mice
Finally, we evaluated the in vivo applicability of the tet
system in tumor-bearing mice. It is known that a s.c.
injection of 5 3 10
6 parental MeWo cells leads to tumor
growth in 100% of nu/nu mice.
22 In the reported exper-
iment, nu/nu mice received a s.c. inoculation of 5 3 10
6
transduced and nontransduced MeWo cells. One group
of mice inoculated with transduced MeWo-tTA/IL-2
Figure 3. Expression of IL-2 decreases with increasing doses of tet. Results of RT-PCR (A) and CTLL-2 (B) bioassays are shown. A: RNA from
MeWo-tTA/IL-2 cells was isolated and reverse transcribed; the cDNA was ampliﬁed using speciﬁc primers for the respective genes IL-2 and
glyceraldehyde-3-phosphate dehydrogenase. Ampliﬁed products were separated on a 1% agarose gel stained with ethidium bromide. B: IL-2
production was determined with the CTLL-2 bioassay. IL-2 levels were evaluated as U/10
6 cells/24 hours.
Table 2. Cytotoxic Activity of NK Cells Against MeWo Cells
Cell line* % Speciﬁc lysis†
MeWo 10.3
MeWo 1 tet 10.7
MeWo 1 rIL-2 55.6
MeWo 1 rIL-2 1 tet 53.9
MeWo-tTA/IL-2 60.0
MeWo-tTA/IL-2 1 tet 10.3
* Spleen cells from nu/nu mice were cultured for 6 days with
irradiated parental untransduced MeWo cells (in the absence or
presence of tet and in the absence or presence of exogenous
IL-2; rIL-2) and transduced MeWo cells (MeWo-tTA/IL-2 in the
absence or presence of tet).
† Cytotoxicity against
51Cr target MeWo cells in a 4-hour
release assay is shown (effector to target ratio 5 25:1).
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group received water without the antibiotic. No tumor
growth was observed in the group of animals receiving
the transduced MeWo-tTA/IL-2, which underlines the
efﬁcacy of the antitumor immune response induced by
tumor cells expressing IL-2. The growth rate of MeWo-
tTA/IL-2 when mice received tet in drinking water did
not signiﬁcantly differ from the growth rate of parental
MeWo cells (Fig 4). This result demonstrates that IL-2
production in the injected tumor cells can be switched
off in vivo by an oral administration of tet. This ﬁnding is
particularly worthwhile, considering that the tumor cells
were implanted into the subcutis, which is not an easily
accessible region.
DISCUSSION
The feasibility of regulating the expression of biologi-
cally active substances such as hormones, cytokines, or
chemokines could be of great clinical importance in
tumor therapy, but also in autoimmune diseases and
chronic infections. To explore the possibility of in vivo-
regulated expression of the cytokine IL-2, we have used
the classical two-plasmid tet system as delineated by
Gossen and Bujard
1 and modiﬁed it as a retroviral
system to transduce the tTA gene and the human IL-2
gene simultaneously in the human melanoma cell line
MeWo. We could demonstrate regulation of IL-2 ex-
pression in vitro as well as in vivo. In the latter situation,
IL-2 expression could be regulated systemically (i.e., in a
s.c. growing tumor by oral application of tet). In agree-
ment with previous results, we observed neither in vitro
nor in vivo leakiness of the binary system.
1,2,11
To test the functionality of the new constructed
retroviral transactivator construct SF6tTA, we tran-
siently transfected NIH3T3 and HeLa cells. Because
there is no retroviral reporter construct available, we
had to use the original nonretroviral luciferase reporter
plasmid, in which the luciferase reporter gene is placed
downstream of the chimeric tetO/CMV minimal pro-
moter. We also had to transiently transfect it before the
target cells were infected with the SF6tTA-containing
supernatant. The determination of the luciferase activity
in the absence of tet revealed up to a 500-fold induction,
which was tightly regulated. Because the reporter plas-
mid was not of a retroviral origin, the induction rate as
well as the tight regulation cannot be directly transmit-
ted to the retroviral system. Nonetheless, transient trans-
fection with the retroviral transactivator construct
SF6tTA allowed us to prove the functionality of the
retroviral tTA vector construct.
When generating the MeWo-tTA/IL-2 cells, we noted
that distinct clones produced variable amounts of IL-2,
whereby it should be noted that the amount of IL-2
production was a stable feature of the individual clones.
All functional studies were pursued with a clone that
produced 40 U/10
6 cells/24 hours. This dose has been
reported by several groups to be the appropriate range
to induce an antitumor immune response.
16,23 The efﬁ-
ciency of IL-2 production by MeWo-tTA/IL-2 to initiate
the activation of NK cells was proven in vitro as well as
in vivo. Spleen cells of nu/nu mice exhibited a signiﬁ-
cantly higher cytotoxic potential against MeWo cells
after coculture with transduced MeWo-tTA/IL-2 than
after coculture with untransduced MeWo cells. Al-
though a similar increase in cytotoxic activity could be
achieved by the addition of exogenous IL-2, the cyto
Figure 4. Tumorigenicity of transduced MeWo-
tTA/IL-2 cells and in vivo inhibition of IL-2
expression by a tet exposure. Groups of six
mice in each category were injected with 5 3
10
6 cells as indicated. MeWo-tTA/IL-2 plus tet
mice received 200 mg/mL tet in drinking water.
The mean diameters 6 SD of the s.c. growing
tumors are shown. Animals were killed after 60
days. Macroscopic and histological evalua-
tions at the implantation site and of different
organs such as the liver and lung did not reveal
any sign of tumor growth in the MeWo-tTA/IL-
2-treated mice.
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IL-2 in the presence of tet displayed only background
cytolytic activity. The fact that the addition of tet to
cultures containing exogenous IL-2 did not inﬂuence
LAK activation proves that the applied concentration of
tet was not toxic. In vivo, the amount of IL-2 expressed
by the transduced MeWo cells was sufﬁcient to com-
pletely prevent tumor growth, whereas an application of
tet in drinking water was sufﬁcient to fully restore
tumorigenicity (i.e., in the presence of tet, the trans-
duced MeWo showed a comparable growth rate with
untransduced MeWo cells). As demonstrated in vitro
and controlled in vivo (data not shown), tet had no affect
on NK/LAK activity. Thus, the restoration of tumor
growth cannot be assigned to an impaired immune
defense, but most likely will be attributable to the
switch-off of IL-2 production. It is already known that a
supply of tet in drinking water leads to a continuous
dissemination of the antibiotic in different tissues,
whereby tet is readily absorbed and broadly distributed
without toxicity at the concentration needed to regulate
the activity of the promoter.
10 This was demonstrated
for vascularized tissues such as the liver in transgenic
mice.
10 We have proven that the antibiotic also easily
accesses nonvascularized tissue, such as a depot of
tumor cells in a s.c. pocket. This assumption derives
from the observation that the effect of inhibiting IL-2
expression was readily visible already at the start of
tumor growth (i.e., at 10 days after application of the
tumor cells and tet, respectively).
Thus, although the in vivo applicability of the tet
system has already been shown using transgenic expres-
sion systems in animals carrying the tTA and the gene of
interest
7–10 or by directly injecting the gene into the
tissue,
24,25 we have demonstrated for the ﬁrst time the in
vivo feasibility of the retroviral tet-regulated system in
gene therapy with IL-2 transduced tumor cells in the
mouse.
Independent of the discussion for the need for differ-
ent retroviral expression vectors or promoters to achieve
optimal expression of the gene of interest, the described
in vivo manipulation of gene expression in transduced
tumor cells with the tet-regulated system provides per-
spectives on gene therapy. The off-on regulation and,
even more signiﬁcant, the ﬁne tuning, could be of
advantage in the expression of certain genes for which
efﬁcacy is tightly linked to an optimal level of gene
expression. Beyond this, the use of a bidirectional pro-
moter
11 allows for the possibility of two different genes
being distinctly coregulated.
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